The NR1I2 antibody is a crucial tool for studying the nuclear receptor subfamily 1. group I, member 2 (NR1I2), also known as the pregnane X receptor (PXR). PXR is a ligand-activated transcription factor that regulates the expression of genes involved in drug metabolism, detoxification, and transport, including cytochrome P450 enzymes (e.g., CYP3A4) and multidrug resistance proteins. It plays a central role in xenobiotic and bile acid homeostasis by sensing lipophilic compounds, such as pharmaceuticals, environmental toxins, and endogenous molecules, and orchestrating adaptive transcriptional responses.
NR1I2 antibodies are widely used in research to detect PXR expression, localization, and activity in tissues like the liver, intestine, and kidney. They enable techniques such as Western blotting, immunohistochemistry, and chromatin immunoprecipitation (ChIP) to investigate PXR's regulatory mechanisms, ligand interactions, and crosstalk with other nuclear receptors (e.g., CAR, FXR). These antibodies are essential for exploring PXR's role in drug-drug interactions, metabolic diseases, and cancer chemoresistance.
Given PXR's clinical relevance in modulating drug efficacy and toxicity, NR1I2 antibodies also support drug development efforts targeting PXR activation or inhibition to optimize therapeutic outcomes. Research using these antibodies continues to unravel PXR's complex roles in physiology and disease.